RITUXIMAB (MabThera®) for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated (ANCA) Vasculitis (AAV) - Pan Mersey APC Skip to main content Help with accessibility Skip to main navigation

RITUXIMAB (MabThera®) for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated (ANCA) Vasculitis (AAV)

Last Updated: 15 November 2017

Body System: Immune system

NHS England

NHS England specialised commissining resources: the clinical reference group responsible for specialised rheumatology has published a commissioning policy that defines access to a particular service for a cohort of patients.